Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TARS1 | P26639 | 2/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413061 | 1.00 | HTR2B (0.35) | HTR2BHTR2CADORA3ADORA1ADRA2B | |
| SCHEMBL16987222 | 0.86 | TARS1 (0.38) | ADORA1TARS1 | |
| SCHEMBL29435121 | 0.86 | TARS1 (0.38) | ADORA1TARS1 | |
| SCHEMBL28564130 | 0.86 | TARS1 (0.38) | ADORA1TARS1 | |
| SCHEMBL29238711 | 0.86 | HTR2B (0.34) | HTR2BHTR2CADORA3ADRA2BHTR2A | |
| SCHEMBL29043762 | 0.85 | KDM4E (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL29407144 | 0.85 | KDM4E (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL31192291 | 0.81 | HTR2C (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL28521252 | 0.81 | HTR2C (0.31) | HTR2BHTR2CKDM4EPKM | |
| SCHEMBL28894185 | 0.79 | ADORA3 (0.54) | ADORA3ADORA1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119421870-A | Lipid compound and application thereof | 传信生物医药(苏州)有限公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119384273-A | Organ-specific delivery compositions for nucleic acids | 传信生物医药(苏州)有限公司 | 2025-01-28 | — | — | CN | claimed |
| CN-117866948-B | Negative selection method and system for purifying circular nucleic acid | 上海环码生物医药有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-118660973-A | RNA and DNA analysis Using engineered surfaces | 阿丽达生物科学公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118613500-A | Modified mRNA treatment | 沙塔克实验室有限公司 | 2024-09-06 | — | — | CN | claimed |
| CN-118475599-A | Chimeric proteins for the treatment of skin inflammation | 沙塔克实验室有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-117500823-A | Chimeric proteins in autoimmunity | 沙塔克实验室有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117413065-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-111744019-B | Mannose-based mRNA targeted delivery system and application thereof | 深圳瑞吉生物科技有限公司 | 2023-08-04 | — | — | CN | claimed |
| CN-114502204-A | RNA combinations and compositions with reduced immunostimulatory properties | 库尔维科公司 | 2022-05-13 | — | — | CN | claimed |
| CN-112390871-A | In vivo production of proteins | 现代泰克斯公司 | 2021-02-23 | — | — | CN | claimed |
| CN-113396219-B | Purification of mRNA by tangential flow filtration | ETHRIS GMBH (DE) | 2026-05-26 | — | — | CN | disclosed |
| CN-122074087-A | Reverse transcription mediated gene editing system and use thereof | 阿伯生物技术公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | disclosed |
| CN-122029278-A | Constructs, methods and uses for the preparation of circular RNAs | 上海环码生物医药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-110891553-A | Method for producing liposome encapsulating RNA | 葛兰素史密丝克莱恩生物有限公司 | 2020-03-17 | — | — | CN | disclosed |
| CN-110799644-A | CBLB endonuclease variants, compositions, and methods of use | 蓝鸟生物公司 | 2020-02-14 | — | — | CN | disclosed |
| CN-110582304-A | RNA for treating or preventing liver disease | 库尔维科公司 | 2019-12-17 | — | — | CN | disclosed |
| CN-110505877-A | RNA cancer vaccine | MODERNATX INC | 2019-11-26 | — | — | CN | disclosed |
| CN-105308183-A | Compositions and methods of altering cholesterol levels | modeRNA Therapeutics | 2016-02-03 | — | — | CN | disclosed |